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Summary 
A  rat model of inflammation was used to investigate the biological effects of thrombin. The 
thrombin-specific inhibitor Hirulog  TM  markedly attenuated the carrageenin-induced edema of 
the paw of the rat.  Injection of thrombin into the paw also produced edema. The effect of 
thrombin was due to activation of its receptor; a thrombin receptor activating peptide (TRAP) 
reproduced the effects of thrombin in causing edema. TRAP also increased vascular permeabil- 
ity as demonstrated by extravasation of Evans blue and 125I-labeled serum albumin. The release 
of bioactive amines played an important role in mediating the TRAP-induced edema; the se- 
rotinin/histamine antagonist cryproheptadine and the histamine H2 receptor antagonist cimeti- 
dine reduced significantly the edema caused by TRAP. Treatment of rats with the mast cell de- 
granulator 48/80 to  deplete these  cells  of their stores  of histamine  and serotonin abolished 
completely the ability of TRAP to produce edema. Histochemical examination confirmed that 
TRAP treatment led to mast cell degranulation. Thus, it has been possible to demonstrate that 
thrombin acts  as an inflammatory mediator in vivo by activating its  receptor, which in turn 
leads to release of vasoactive amines from mast cells. 
T 
hrombin is a trypsinlike serine protease that has a cen- 
tral role in hemostasis and thrombosis. It is generated 
as  a  result  of the  activation  of the  coagulation  cascade. 
Once formed, thrombin cleaves fibrinogen to produce the 
fibrin mesh of the blood clot. Thrombin also exerts a posi- 
tive feedback on its own production by activating factors V 
and VIII which are essential cofactors in the cascade.  Natu- 
ral anticoagulant mechanisms limit these processes; throm- 
bin is  inactivated by antithrombin  III,  and  in  a  complex 
with thrombomodulin, it activates protein C which in turn 
shuts  down the coagulation cascade.  Thus, under physio- 
logical conditions, this balance between pro- and anticoag- 
ulant mechanisms allows the local generation of thrombin 
and prevents systemic coagulation (1). 
The main features of the inflammatory response are:  (a) 
vasodilation, allowing increased blood flow to the affected 
area;  (b) increased vascular permeability, permitting diffus- 
ible components to enter the site;  and  (c) cellular infiltra- 
tion by chemoataxis. All these processes are induced by sol- 
uble molecules that act locally at the site  of tissue  damage 
or infection; these molecules are known as  inflammatory 
mediators and  include molecules such  as  IL-1,  IL-6,  and 
TNF.  Inflammatory mediators  can  also  be  derived from 
molecules that  are normally present in plasma  in inactive 
forms, such as peptide fragments of some components of 
the complement, coagulation, and kinin systems  (2). 
Fibrin deposition is an integral feature of the inflamma- 
tory response to a variety of  stimuli including thermal, chem- 
ical,  or physical trauma (3, 4), indicating activation of the 
coagulation system and generation of thrombin at the site 
of inflammation. Besides catalyzing the formation of fibrin, 
thrombin also induces several of the cellular responses in- 
volved in inflammation. Activation of platelets by throm- 
bin causes the release of 5-hydroxytryptamine (serotonin), 
a potent vasodilator (2).  In  addition,  thrombin  stimulates 
the secretion of other inflammatory mediators; for exam- 
ple, it causes  mast cell degranulation with release of hista- 
mine  (5)  and  promotes  production  of IL-1  by  activated 
macrophages  (6).  Thrombin also  directly mediates several 
inflammatory responses.  It increases vascular permeability 
(7) and promotes transendothelial cell migration by neutro- 
phils (8). This latter effect ofthrombin is due to at least two 
cellular responses to thrombin. Thrombin enhances adhe- 
sion of neutrophils to endothelial cells by increasing surface 
expression of P-selectin (9-11). In addition, thrombin acts 
as  a  chemotactic agent for neutrophi|s  (12,  13).  Many of 
the  cellular effects of thrombin involve its  proteolytically 
activated receptor. Thrombin  activates this  receptor by a 
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main of the receptor and the newly created NH2-temfinus 
then  acts  as  a  "tethered  ligand"  (14).  Synthetic  peptides 
corresponding to the tethered ligand are able to activate the 
receptor in  the  absence  of thrombin  (14)  and  are  termed 
thrombin receptor activating peptides (TRAP)J The throm- 
bin receptor has been shown to mediate thrombin-induced 
vasodilation (15),  increased vascular permeability (16),  and 
neutrophil-endothelial cell adhesion (11). 
Whereas all these observed effects of thrombin suggest a 
possible role for this protease in mediating the  inflamma- 
tory  response,  no  direct  evidence  has  been  obtained  for 
such a role in vivo. In the present study, we have demon- 
strated for the first time a direct role for thrombin as a me- 
diator of inflammation in a rat model. Moreover, the results 
indicated that thrombin functions as an inflammatory me- 
diator through  activation of its receptor.  Thus,  thrombin 
provides an important link between the initial response to 
injury  (blood coagulation)  and  the later cellular responses 
required for healing (inflammation). Thrombin may also be 
important in inflammation not related to healing where in- 
filtrating leukocytes often express cell-associated procoagu- 
lant activity that leads to thrombin generation (17). 
Materials  and Methods 
Materials.  TRAP  (SFLLRNPNDKYEPF),  the  control TRAP 
peptide  (SFLLANPNDKYEPF),  and  Hirulog  (Biogen,  Cam- 
bridge, MA) were prepared as previously described (18,  19). Hu- 
man  thrombin,  compound  48/80,  k  carrageenin, mepyramine, 
and cyproheptadine were purchased from Sigma Chemical Co. 
(St. Louis, MO). Cimetidine was a gift of Dr. Calignano (Univer- 
sity of Naples, Naples, Italy). 
Measurement of Edema Formation in the Rat Paw Edema.  Male 
Wistar rats (Charles River, Milan, Italy) weighing 120-150 g were 
divided in groups of five and lightly anesthetized with ether. Each 
group of animals received subplantar  administration of 0.1  ml of a 
solution containing thrombin (1  or 10 L0, TRAP  (1-500 v~g), or 
carrageenin  (1%} wt/vol) in PBS. Paw volume was measured using a 
hydroplethismometer (Ugo Basile, Milan, Italy) immediately before 
the subplantar  injection, each 15 man during the first hour, and at 
different time intervals thereaficer  for up to 5 h. The increase in paw 
volume was evaluated as difference between the paw volume at each 
interval and the basal paw volume. All edema experiments were re- 
peated at least twice with similar results. 
For the evaluation of the effects of drugs on edema formation, 
groups  of animals were pretreated with cimetidine (50  mg/kg, 
i.p.), mepyramine (5 mg/kg, i.p.), or cyproheptadine (5 mg/kg, 
i.p.)  30  rain  before  TRAP  (500  I.zg/paw)  administration.  In- 
domethacin was given at a dose of (5 mg/kg, i.p.) 15 rain before 
TRAP  administration.  Hirulog  (1-5  mg/kg,  i.v.)  was  injected 
immediately before  the  subplantar  injection  of carrageenin  or 
TRAP. 
Depletion of  Histamine and 5-Hydroxytryptamine.  Groups of five 
rats  were  depleted  of their  mast  cell  stores  of histamine  and 
5-hydroxytryptamine by repeated injection of the compound 48/ 
80 as described by Di Rosa et al.  (20).  Briefly, a solution (0.1% 
wt/vol) of compound 48/80 in physiological saline was injected 
1Abbreviation used in this paper: TRAP, thrombin receptor activating pep- 
tides. 
intraperitoneaUy morning and  evening for  eight doses,  starting 
with an evening dose. The doses employed were 0.6 mg/kg for 
the first six injections and 1.2 mg/kg for the last two administra- 
tions.  The  efficacy of the  treatment was shown  by the lack of 
edema for 1 h  after the injection of carrageenin in the depleted 
animals. TRAP (100 or 500 Ixg) was injected 5-6 h after the last 
injection of compound 48/80. 
Measurement  of Extmvasation  of Evans  Blue  in  the  Rat  Paw. 
Evans blue solution (2.5% wt/vol; 25 mg/kg) was injected intra- 
venously immediately before the subplantar injection of TRAP 
(1-500 }xg) or the control TRAP peptide (500 }xg). After 15 rnin, 
rats were killed; the paw was removed, homogenized, and stored 
in formamide (10 ml) for 72 h at 37~  to allow Evans blue ex- 
traction. Each solution was  then  filtered and the absorbance of 
the filtrate assessed at 619  nm  (21).  Each treatment group con- 
sisted of six rats. 
Measurement of Local Edema Formation in Rat Dorsal Skin  with 
125I-labeled Albumin.  Local edema  formation was  measured  in 
male Wistar rats (150-200 g) as the local accumulation of 125I-labeled 
human serum albumin into skin sites (22, 23). Rats were anesthe- 
tized with sodium pentobarbitone (45  mg/kg, i.p.). The  dorsal 
skin was shaven and a solution of Evans blue (0.5 ml/kg of 2.5% 
wt/vol)  containing ~25I-labeled human  serum albumin  (2  ~zCi/ 
kg) was injected intravenously. TRAP (10 or 100 wg) or the con- 
trol TRAP peptide (100 ~g) was injected intradermally in a final 
volume of 100 ~1 into the shaved dorsal surface  using a balanced 
site pattern of six injections, that is, three control and three treat- 
ment injections were symmetrically arranged on opposite sides of 
the dorsal midline. Six replicates were performed. Blood samples 
(1 ml) were taken into heparin by cardiac puncture after 15 min. 
The rat was decapitated and the dorsal skin was removed. The in- 
jection sites were punched out (5-mm diameter) and the radioac- 
tivity of both the skin and the plasma sample were determined. 
Edema formation at each site was expressed as plasma volume cal- 
culated on the basis of radioactivity in 1 ml of plasma. 
Histochemistry.  Rats were given a 0.1-ml subplantar injection 
of TRAP  (100 or 500  ~g)  or PBS and killed after 15 rain. The 
injected paws were removed and fixed in neutral buffered forma- 
lin  before  being  embedded  in  paraflfin. Sections  (4  ~m)  were 
stained with Alcian blue and counterstained with hematoxylin. 
Statistical Analysis,  All results are reported as mean  -  SEM. 
The unpaired Student's t test was used for statistical evaluation of 
the results  when  two groups were compared. When more than 
two  groups  were  compared,  analysis  of variance  followed by 
Dunnett's test was used. A value ofp <0.05 was taken as signifi- 
cant. In some cases, the extent of the edema was evaluated as area 
under the curve of increase in paw volume versus time according 
to the trapezoidal rule. 
Results 
Role for  Thrombin  in  the  Acute  Inflammatory  Response  to 
Carrageenin.  To investigate a possible role for thrombin in 
the acute inflammatory response, the effect of the thrombin 
inhibitor Hirulog on  carrageenin-induced edema  was  ex- 
anained. Hirulog is a specific inhibitor ofthrornbin, binding 
to the active site and anion-binding exosite of the protease 
(18, 24). At all doses tested (1, 2, and 5 mg/kg), treatment 
with Hirulog suppressed the normal response to subplantar 
injection of carrageenin at the earliest time point (1 h; Fig. 
1).  However,  the  edema  induced  by  carrageenin  at  later 
times  (>3  h) was only significantly reduced by the higher 
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(5 mg/kg),  edema  formation was  largely  suppressed  over 
the entire time course of the experiment (5 h; Fig.  1). 
The results obtained with Hirulog suggested that throm-  0.3- 
bin is a mediator of the acute inflammatory response to car- 
rageenin.  The  ability  of thrombin  to  induce  edema  was 
confirmed  by  subplantar  injection  of thrombin  into  the  ~  0.2- 
hind paw. At the lower concentration  (1  U/paw), throm- 
bin caused a transient edema; the paw volume peaked at 15  0.1 
rain and returned  to baseline by 60 rain  (Fig.  2 A). With 
the  higher  concentration  (10  U/paw),  the  edema  also 
peaked at  15  rain, but had not returned to baseline by 90  0 
min (Fig. 2 A). 
Thrombin-induced  Edema  Is  Mediated  by  Activation  of the 
Thrombin Receptor.  Peptides that activate the thrombin re- 
ceptor were used to investigate the mechanism by which 
0.4  thrombin produced edema. Thrombin activates its receptor 
by cleavage and the newly generated NH  2 terminus acts as 
a tethered ligand for the receptor. Peptides corresponding  0.3- 
to the tethered ligand can activate the receptor in the ab- 
sence of cleavage (14).  A  TRAP reproduced the effects of 
thrombin  (Fig.  2  B).  A  dose-dependent increase in edema  -~  o.2- 
was  observed.  Lower  concentrations  of TRAP  (1  or  10 
p,g/paw) produced edema by 15 rain that had returned to 
baseline  by 45  rain.  With  higher  concentrations  (100  or  0.1 
500  pLg/paw), greater edema was observed at 15 min, and 
with  the  highest  concentration,  the  edema persisted until 
90 min. The edema induced by TRAP was not due to ac-  0.0 
tivation of the coagulation cascade. Hirulog (5 mg/kg) did 
not reduce the edema in response to 500  p,g TRAP  (data 
not shown). The response to TRAP was specific. Previous 
studies have shown that replacement of the arginine in po- 
sition 5 of TRAP by alanine reduces markedly the agonist 
activity of TRAP  (19,  25).  Injection of the  peptide  with 
alanine substituted in the position five (500  p~g) produced 
significantly less edema than the equivalent dose of TRAP 
(p <0.01;  n =  5; Fig. 2 B). 
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Figure  1.  Inhibitory  effect  of Hirulog  on  carrageenin-induced  paw 
edema. Edema was induced in the rat hind paw by a subplantar injection 
of 0.1  ml 1% (wt/vol) carrageenin and the increase  in paw volume mea- 
sured as described in Materials  and Methods. Hirulog was given as an in- 
travenous  injection  immediately  before  carrageenin  at  the  following 
doses: 0 (m), 1 (O), 2 ('), or 5 mg/kg (A). *p <0.05, **p <0.01  (n =  5). 
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Figure 2.  Thrombin and TRAP cause paw edema. Edema was induced 
in the rat hind paw by a subplantar injection of 0.1  ml solution of either 
thrombin (A) or TRAP (/3); the increase  in paw volume was measured as 
described  in Materials  and Methods.  (A) Thrombin was administered at 
the following doses:  1 (0) or 10 U/paw (I). (B) The TRAP doses used 
were:  1 (O),  10  ('),  100  (O), or 500 ~g/paw (A). The control TRAP 
(SFLLANPNDK-YEPF) at a dose of 500 p~g/paw  (V) produced signifi- 
candy less edema (p <0.01; n  =  5) at all time points than the equivalent 
dose of TRAP. 
The ability of TRAP to induce components of the acute 
inflammatory response was confirmed in two other experi- 
mental models. An increase in vascular permeability leading 
to extravasation of plasma proteins is an important compo- 
nent of inflammation. TRAP could induce this extravasation. 
Intravenous injection  of either Evans blue  or  125I-labeled 
serum albumin was  used  to  evaluate increases  in  vascular 
permeability. Subplantar injection of TRAP into the hind 
paw led to an increase in the amount of Evans blue leaking 
into the paw (Fig. 3). Significant increases in the amount of 
Evans blue in the paw were observed with 100 and 500 p,g 
TRAP compared with 500 p~g control TRAP. In addition, 
intradermal injection  of TRAP  into  dorsal sites  led to an 
accumulation of serum albumin at these sites.  TRAP  (100 
p~g) led to the accumulation of the equivalent of 48  -+ 4 p,1 
plasma/site compared with 24  +  11  p]/site for the control 
TRAP (100 p,g; p  <0.05, n =  6). 10" 
8- 
6- 
4- 
2- 
ol 
T  T  T  ""1" 
Jl  Jl  I 
i  i  /  I 
C  1  10  100 
i 
i 
500 
TRAP  (lag) 
Figure 3.  TRAP induces increases in vascular  permeabihty. The effect 
of TtLAP at different doses (~g/paw) on vascular permeability was evalu- 
ated by the accumulation of Evans blue in the paw after subplantar injec- 
tion as described in Materials and Methods. (C) Response to the control 
TRAP (SFLLANPNDKYEPF) at a dose of 500 Ixg/paw. The responses 
to 100 and 500 btg TRAP were significantly  evaluated compared with the 
control; *p <0.05,  **p <0.01  (n =  6). Data similar to those shown were 
obtained on two other occasions. 
The results presented in Fig. 4  established that bioactive 
amines produced by mast cells were the principal mediators 
of the edema caused by TRAP. Rats were treated with the 
mast cell degranulator 48/80  to deplete these cells of their 
stores of serotonin  and  histamine.  Complete  depletion of 
these stores was confirmed by the absence of edema in re- 
sponse to carrageenin in treated rats. Treatment with com- 
pound  40/80  did  not  affect  significantly the  numbers  of 
circulating platelets, neutrophils, and lymphocytes in com- 
parison  with  saline-treated controls.  As  shown  in  Fig.  4, 
pretreatment  of rats with  48/80  completely abolished the 
ability of TRAP  to cause edema. 
Histochemical examination indicated that  TRAP  treat- 
ment had caused mast cell degranulation (Fig. 5).  Injection 
of TRAP led to the loss of tissue organization characteristic 
of edema (Fig. 5  B). The granules of mast cells contain hep- 
arin as well as histamine and serotonin. In sections from the 
paws injected with buffer control,  mast cells stained posi- 
tively with Alcian blue because of the presence of heparin 
in  the  granules  (Fig.  5  A).  After TRAP  treatment,  how- 
ever, mast cells failed to take up Alcian blue because of the 
release of their granule contents (Fig. 5 B). 
Bioactive Amines  Are  Involved in  TRAP-induced  Edema. 
The  edema induced by TRAP  was  rapid in  onset  and  of 
short duration. The most important mediators of the early 
phase  of the inflammation response involving vasodilation 
and  increase  in  vascular  permeability  are  the  bioactive 
amines histamine and 5-hydroxytryptamine (serotonin) se- 
creted by mast cells and platelets after activation. Thus, two 
mechanisms  for the  TRAP-induced  edema seemed possi- 
ble: either (a)  TRAP  acted directly on endothelial cells to 
increase vascular permeability; or (b) the effects were due to 
stimulation of mast cells and/or platelets to release vasoac- 
tive amines. It was possible to distinguish between the two 
possibilities by using histamine/serotonin receptor antago- 
nists  and  by  depleting mast  cells  of endogenous  amines. 
Treatment  of rats with the serotonin/histamine antagonist 
cyproheptadine and  the  histamine  H2  receptor antagonist 
cimetidine  significantly  reduced  the  edema  caused  by 
TRAP.  Edema formation was measured as the area under 
the curve for data similar to those shown in Fig. 2  B  after 
subplantar injection of 500 btg TRAP. Cyproheptadine and 
cimetidine reduced the TRAP-induced edema by 57  +  8% 
and 47  +  12%, respectively (p <0.05;  n  =  5). Cyprohepta- 
dine has been shown to cause a similar decrease in seroto- 
nin-induced edema at an equivalent dose (26, 27).  In con- 
trast, the histamine H1 receptor antagonist mepyramine did 
not affect significantly the extent of the edema due to 500 
btg TRAP; a 27  +  14% reduction was observed. Thrombin 
has also been shown to stimulate the production of the va- 
soactive eicosanoids thromboxane A 2 and prostacyclin (28). 
These  compounds  do not,  however,  seem to be involved 
in TRAP-induced edema. Blocking their synthesis with in- 
domethacin  had  little effect  on  the  edema  in  response  to 
500  b~g  TRAP  (indomethacin  treatment  caused  a  20  + 
16% decrease in edema). 
Discussion 
The thrombin-specific inhibitor Himlog attenuated greatly 
the edema produced by carrageenin (Fig. 1).  Higher doses 
of Hirulog dampened both the initial and later responses to 
carrageenin.  These  results  suggest  a  role  for  thrombin  in 
both phases of the carrageenin-induced edema. The  initial 
phase  of the  response  to  carrageenin is largely due  to  the 
release of histamine and serotonin from mast cells and the 
later phase  occurs when  polymorphonuclear cells migrate 
into  the  site  (29).  Thus,  the  results  with  Hirulog suggest 
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Figure  4.  Depletion  of bioacnve  amines abolishes TRAP-induced 
edema. Rats were treated with 48/80  to deplete their mast cell stores of 
histamines and serotonin, and TRAP was given by subplantar injection 
after completion of the treatment. Two groups received sahne instead of 
48/80 before administration of T1LAP at doses of 100 (11) or 500 p.g/paw 
(0). The groups treated with 48/80 failed to respond to TRAP at doses 
of 100 (0) or 500 b~g/paw (i). **p <0.01  (n = 5). The complete inhibi- 
tion of the TRAP response by treatment with 48/80  was also observed 
when the experiment was repeated on two further occasions. 
824  Thrombin in Inflammation Figure 5.  TRAP treatment causes mast cell degranulation. 1Kats  were given a 0.1 ml subplantar injection ofPBS (A) or TRAP (500 lag in PBS; B). Rat 
paws were processed for histochemical examination as described in Materials and Methods and sections were stained with Alcian blue and counterstained 
with hematoxyhn. In the control section (A), mast cells stained blue (arrows), After TRAP treatment, mast cells (arrows) failed to stain with Alcian  blue, in- 
dicating degranulation. X  600. 
that thrombin acts both by stimulating the release ofbioac- 
tive amines from mast cells and as a chemotactic agent for 
polymorphonuclear  cells.  The  effect  of thrombin  in  the 
initial phase of edema formation appears to involve the ac- 
tivation  of the  thrombin  receptor;  low  concentrations  of 
TRAP (1 or 10 I~g/paw) caused a transient edema and more 
persistent  edema  was observed with  higher concentrations 
(100  or  500  Ixg/paw;  Fig.  2  B).  The  edema  caused  by 
TRAP appeared to be mediated by the release of bioactive 
amines from mast cells.  Histamine/serotonin  antagonists re- 
duced the TRAP-induced edema and depletion of  stores of 
bioactive amines in mast cell granules by compound 48/80 
abolished  completely the  ability  of TRAP  to  cause  edema 
(Figs.  3 and 4). Moreover, histochemical examination con- 
firmed that treatment with TRAP caused mast cell degran- 
ulation (Fig. 5). The complete suppression of  TRAP-induced 
edema  by  chronic  treatment  with  compound  48/80  was 
particularly striking  (Fig.  4).  Although it is  difficult to ex- 
clude that compound 40/80  does not affect other cells in- 
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volved in  the inflammatory response,  previous studies in- 
dicate that the major effect of this  compound is to deplete 
mast  cells  of their  stores  of bioactive  amines,  whereas  en- 
dothehal  cells,  platelets,  and  leukocytes  are  not  markedly 
affected  (30--32).  From the  results  obtained  in  the present 
study, it is not possible to evaluate whether TRAP directly 
induces  mast  cell  degranulation  and  release  of bioactive 
amines.  Alternatively,  this  degranulation  may be mediated 
by the effect of TRAP on other cells which in turn release 
substances  capable  of promoting  mast  cell  degranulation. 
However, a previous in vitro study has shown that throm- 
bin can cause degranulation of  mast cells with the concom- 
itant  release  of serotonin and histamine  (5).  In conclusion, 
our results indicate that TRAP (and thrombin) cause edema 
by  stimulating  directly  or  indirectly  mast  cells  to  release 
bioactive amines which in turn cause the increase in vascu- 
lar permeability that is necessary for edema formation (33). 
Although the results obtained with TRAP suggest a role 
for activation of the thrombin receptor in the initial phase of edema formation, the transient response to TRAP indi- 
cates that activation of the receptor may not be involved in 
the later phase of the response. The ability of Hirulog to at- 
tenuate this later phase suggests that thrombin may be act- 
ing  independently  of its  receptor  in  this  phase.  The  in- 
volvement  of the  thrombin  receptor  in  the  later  phase 
cannot, however, be ruled out since TRAP may be short- 
lived at the site of inflammation; TRAP is rapidly degraded 
in plasma by aminopeptidase M  (34). Nevertheless,  there is 
evidence  that  thrombin-induced  neutrophil  chemotaxis 
does not involve the receptor activated by TRAP. Inactive 
thrombin,  which will  not activate the  thrombin  receptor, 
stimulates  neutrophil  chemotaxis  (12,  35).  Thus,  it  seems 
possible that thrombin could stimulate the accumulation of 
leukocytes at the site of inflammation through activation of 
a distinct  (chemotactic) receptor. The ability of Hirulog to 
attenuate  the later  response  to  carrageenin  may be related 
to its ability to bind to sites  on thrombin other than the ac- 
tive site; the results ofRowand et al.  (13) indicate that neu- 
trophil chemotaxis would be blocked by Hirulog's binding 
to the anion-binding exosite of thrombin. 
Overall,  our  results  indicate  that  thrombin  may be  an 
important  mediator  of the  acute  inflammatory  response. 
Thrombin will be formed as a result of vascular injury. Al- 
ternatively,  exposure  of endothelial  cells and macrophages 
to inflammatory stimuli, such as LPS and IL-1, leads to the 
expression  of cell-associated procoagulant activity with re- 
sukant thrombin generation  (17).  Once formed,  thrombin 
could stimulate release ofvasoactive amines from mast cells 
(5) and act as chemoattractants for neutrophils (12,  13, 35). 
Thrombin  may also  cause  the  secretion  of additional  in- 
flammatory mediators  (6,  36, 37) and recruit other cells  to 
the site of inflammation (38). The results indicate synthetic 
thrombin inhibitors, such as Hirulog, may be useful in con- 
trolling inflammation. 
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